Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MIRA Mira Pharma

Trading 03-02 11:46:00 EST

1.23

-0.04

-3.09%

High1.26	Low1.10	Vol223.67K
Open1.22	D1 Closing1.27	Amplitude12.99%
Mkt Cap51.54M	Tradable Cap43.01M	Total Shares41.88M
T/O255.59K	T/O Rate0.64%	Tradable Shares34.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":1.2307,"timestamp":1772469592113,"preClose":1.27,"halted":0,"volume":223667,"delay":0,"changeRate":-0.030944881889763867,"floatShares":34944200,"shares":41876087,"eps":-1.611899,"marketStatus":"Trading","change":-0.0393,"latestTime":"03-02 11:46:00 EST","open":1.22,"high":1.26,"low":1.095,"amount":255589.0450071,"amplitude":0.129921,"askPrice":1.25,"askSize":320,"bidPrice":1.23,"bidSize":1130,"shortable":0,"etf":0,"ttmEps":-1.611899,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772485200000},"marketStatusCode":2,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":1.27,"preHourTrading":{"tag":"盘前","latestPrice":1.2017,"preClose":1.27,"latestTime":"09:27 EST","volume":4147,"amount":4971.4961725,"timestamp":1772461660185,"change":-0.0683,"changeRate":-0.05378,"amplitude":0.062756},"postHourTrading":{"tag":"盘后","latestPrice":1.2515,"preClose":1.27,"latestTime":"17:32 EST","volume":1017,"amount":1272.8685,"timestamp":1772231541453,"change":-0.0185,"changeRate":-0.014567,"amplitude":0.000866},"volumeRatio":7.231796},"requestUrl":"/m/hq/s/MIRA/tweets","defaultTab":"tweets","newsList":[{"id":"2612892652","title":"Visionstate Repositions Under MIRA Platform as Subscriptions Accelerate","url":"https://stock-news.laohu8.com/highlight/detail?id=2612892652","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612892652?lang=en_us&edition=fundamental","pubTime":"2026-02-20 00:10","pubTimestamp":1771517459,"startTime":"0","endTime":"0","summary":"The latest update is out from Visionstate ( ($TSE:VIS) ). Visionstate has rebranded and consolidated its technology under the MIRA compliance platf...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/visionstate-repositions-under-mira-platform-as-subscriptions-accelerate?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/visionstate-repositions-under-mira-platform-as-subscriptions-accelerate?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AAQC","BK4007","MIRA"],"gpt_icon":0},{"id":"2609904995","title":"Mira Pharmaceuticals Unveils Pipeline Focused on Oral Therapies for Neurologic and Metabolic Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2609904995","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609904995?lang=en_us&edition=fundamental","pubTime":"2026-02-07 00:27","pubTimestamp":1770395265,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc.  has released an investor presentation outlining its pipeline of oral therapies targeting neurologic, neuropsychiatric, and metabolic disorders. The company highlighted Ketamir-2, a next-generation oral ketamine analog currently in Phase 1 clinical trials for neuropathic pain. Ketamir-2 is designed with improved bioavailability, selectivity, and safety, and Mira Pharmaceuticals is positioning it as a potential first-in-class oral treatment for high-need psychiatric indications, including treatment-resistant depression  and post-traumatic stress disorder . The presentation also details the compound’s scalable and high-yield manufacturing process and complete characterization of its crystalline form. Market opportunities for TRD and PTSD treatments were noted, with steady growth projected in both areas. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intellige","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDLpznWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2609590496","title":"Mira Pharmaceuticals stellt Pipeline für neuartige orale Therapien bei neurologischen und psychiatrischen Erkrankungen vor","url":"https://stock-news.laohu8.com/highlight/detail?id=2609590496","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609590496?lang=en_us&edition=fundamental","pubTime":"2026-02-07 00:27","pubTimestamp":1770395265,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief on February 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL3XvfJD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2608890833","title":"Mira Pharmaceuticals Begins Final Dosing in Phase 1 Trial of Ketamir-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2608890833","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608890833?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:02","pubTimestamp":1770066144,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL2t1GRT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2593489004","title":"Mira Pharmaceuticals Awards CEO Erez Aminov New Incentive Compensation Package","url":"https://stock-news.laohu8.com/highlight/detail?id=2593489004","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593489004?lang=en_us&edition=fundamental","pubTime":"2025-12-22 19:03","pubTimestamp":1766401394,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. has approved new compensation terms for Chief Executive Officer Erez Aminov following significant company achievements in 2025. The approved package includes a short-term incentive payout of $242,258, with an additional $80,753 contingent on the completion of an ongoing Phase 1 clinical study. Aminov will also receive a $915,000 transaction advisory award for his role in the acquisition of SKNY Pharmaceutical, Inc., payable in cash, equity, or a combination of both at his discretion. Additionally, the board has granted 62,500 performance share units to Aminov following the achievement of a market capitalization milestone, with immediate vesting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceutica","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL97lV93:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","LU1674673428.USD","LU1778281490.HKD","LU0289739699.SGD","LU0823416689.USD","LU1093756325.SGD","IE00BFTCPJ56.SGD","LU1035775433.USD","LU1069344957.HKD","BK4532","IE00B19Z9Z06.USD","IE0009355771.USD","BK4585","LU0417517546.SGD","IE0002270589.USD","BK4567","LU1093756168.USD","LU0320765992.SGD","LU2362540622.SGD","LU1430594728.SGD","MIRA","LU2456880835.USD","BK4139","SGXZ57979304.SGD","IE00B894F039.SGD","LU0079474960.USD","LU1674673691.USD","LU2236285917.USD","LU2362541273.HKD","LU0058720904.USD","LU0234570918.USD","IE00BZ9MQY76.HKD","VRTX","BK4588","BK4007","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0256863811.USD","LU0109394709.USD","LU2324357040.USD","LU2362541513.USD","IE0002141913.USD","LU0432979614.USD","SG9999001176.USD","IE00B19Z9P08.USD","LU0889565916.HKD","LU2237438978.USD","IE00B2B36J28.USD","LU0061475181.USD","SG9999001176.SGD"],"gpt_icon":0},{"id":"2593512068","title":"New crypto tokens are failing in 2025: 85% below TGE prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2593512068","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593512068?lang=en_us&edition=fundamental","pubTime":"2025-12-21 23:45","pubTimestamp":1766331900,"startTime":"0","endTime":"0","summary":"New crypto token launches have faced major price declines in 2025, with 84.7% trading below their Token Generation Event valuations.Research by Ash from Memento Research tracked 118 TGE launches this year, finding that 100 tokens have fallen beneath their opening prices.The median token has crashed 71% in fully diluted valuation since launch, with market cap down 67%. Only 15% of 2025 token launches trade above their TGE valuations.“2025 token launches have mostly been a bloodbath,” Ash wrote on X. “This means ~4 out of 5 launches are below their opening valuation.”Syndicate  leads the destruction with a 93.64% decline from its $940 million starting FDV to $59.8 million.Animecoin  fell 93.59% from $870 million to $55.7 million. Berachain  dropped 93.17% from $4.46 billion to $305 million.The data covers both H1 and H2 2025 launches. H1 tokens include Bio Protocol, Xterio, Berachain, and Nillion. H2 tokens include Syndicate, Animecoin, Lit Protocol, Yala, and Towns.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/new-crypto-tokens-failing-in-2025-85-below-tge-prices/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/new-crypto-tokens-failing-in-2025-85-below-tge-prices/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["BK4206","BK4168","BK7111","BK4020","TGE","BIO","BK4138","LU1169590202.USD","XPL.AU","BK4588","BK4077","BK4139","TREE","LU1169589451.USD","BK4007","BK4166","BIO.AU","BK4121","BK4090","BK4214","BK4585","FF","XPL","YALA","BK4109","MIRA","VVV","CAMP"],"gpt_icon":0},{"id":"2583046593","title":"Mira Pharmaceuticals Q3 EPS $(1.18) Misses $(0.08) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583046593","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583046593?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:50","pubTimestamp":1763041807,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals (NASDAQ:MIRA) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(0.08) by 1375 percent. This is a 742.86 percent decrease over losses of $(0.14) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48832547/mira-pharmaceuticals-q3-eps-1-18-misses-0-08-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA"],"gpt_icon":0},{"id":"2577530523","title":"BRIEF-Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577530523","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577530523?lang=en_us&edition=fundamental","pubTime":"2025-10-24 06:38","pubTimestamp":1761259087,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC FilingOct 24  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - INITIATES PHASE 1 STUDY OF KETAMIR-2 - SEC FILINGSource text: [ID:n0001493152-25-019065]Further company coverage: MIRA.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nFWN3W436K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2577318255","title":"MIRA Pharmaceuticals Advances Ketamir-2 Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2577318255","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577318255?lang=en_us&edition=fundamental","pubTime":"2025-10-24 04:40","pubTimestamp":1761252003,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has provided an update. MIRA Pharmaceuticals has initiated the multiple ascending dose (MAD) phase of its Ph...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-advances-ketamir-2-clinical-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-advances-ketamir-2-clinical-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2577816535","title":"Mira Pharmaceuticals Launches Phase 1 Trial of Oral Ketamir-2 for Chemotherapy-Induced Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2577816535","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577816535?lang=en_us&edition=fundamental","pubTime":"2025-10-24 04:02","pubTimestamp":1761249755,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. has announced the initiation of the multiple ascending dose  portion of its ongoing Phase 1 clinical trial evaluating its lead oral candidate, Ketamir-2, in healthy volunteers. The company has also selected chemotherapy-induced peripheral neuropathy  as the lead indication for its planned Phase 2a trial. The Phase 1 study is randomized, double-blind, and placebo-controlled, assessing the safety, tolerability, and pharmacokinetics of Ketamir-2. No serious or dose-limiting adverse events have been observed to date, and no clinically significant safety concerns have been reported. Results from the comprehensive pharmacokinetic analyses will be presented following unblinding. Ketamir-2 is a novel oral analog of ketamine developed to address limitations of current therapies and is being considered for further development in CIPN due to the lack of FDA-approved treatments for this condition.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL8bRsL4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2576755467","title":"MIRA Pharmaceuticals Sells Shares at 66% Premium","url":"https://stock-news.laohu8.com/highlight/detail?id=2576755467","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576755467?lang=en_us&edition=fundamental","pubTime":"2025-10-17 04:37","pubTimestamp":1760647027,"startTime":"0","endTime":"0","summary":"The latest announcement is out from MIRA Pharmaceuticals, Inc. ( ($MIRA) ). On October 16, 2025, MIRA Pharmaceuticals, Inc. sold 1,751,000 shares o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-sells-shares-at-66-premium?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-sells-shares-at-66-premium?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2576786037","title":"Mira Pharmaceuticals Inc - Sells 1,751,000 Shares at $2.19 Each - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2576786037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576786037?lang=en_us&edition=fundamental","pubTime":"2025-10-17 04:04","pubTimestamp":1760645042,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nFWN3VX2NM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2576778680","title":"Mira Pharmaceuticals Raises $3.8 Million Through Block Sale of 1.75 Million Shares at 66% Premium","url":"https://stock-news.laohu8.com/highlight/detail?id=2576778680","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576778680?lang=en_us&edition=fundamental","pubTime":"2025-10-17 04:02","pubTimestamp":1760644957,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. has announced the sale of 1,751,000 shares of its common stock to multiple institutional investors through a block sale. The shares were sold at an average price of $2.19 each, representing a 66% premium to the previous day's closing price. The transaction, facilitated by Rodman & Renshaw via the StockBlock platform, generated gross proceeds of approximately $3.84 million before fees and expenses. No warrants were included in the offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on Octo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL5SbylZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2576333722","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2576333722","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576333722?lang=en_us&edition=fundamental","pubTime":"2025-10-17 02:22","pubTimestamp":1760638967,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) said two phase 3 trials of its investigational drug ulixacaltamide in essential tremor met primary and secondary endpoints.Shares surged nearly 200% as intraday tradi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","MIRA","PRAX","APLM","BK4139"],"gpt_icon":0},{"id":"2575725898","title":"BUZZ-U.S. STOCKS ON THE MOVE-DoorDash, Praxis, Snowflake","url":"https://stock-news.laohu8.com/highlight/detail?id=2575725898","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575725898?lang=en_us&edition=fundamental","pubTime":"2025-10-16 23:51","pubTimestamp":1760629913,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-DoorDash, Praxis, SnowflakeEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL6N3VX0XY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251142724.SGD","LU0251132253.USD","LU1778281490.HKD","JBHT","LU0251131958.USD","LU1633808545.USD","LU1935042488.USD","HYPR","LU1983299246.USD","MIRA","PRU","SATL","TMUS","VERI","WAL","SNOW","SCHW","CMC","AEP","DFLI","LU0122379950.USD","PRAX","LU0321505439.SGD","NEM","PSNL","BK4007","JACK","FFIV","BG","TMO","UAL","SNA","HPE","MMC","IE00BZ1G4Q59.USD","DASH","ZION","GRAL","IE0002270589.USD","TRV","FOSL","AIG","IE00BKPKM429.USD","KEY"],"gpt_icon":1},{"id":"2575728393","title":"BUZZ-MIRA Pharmaceuticals jumps as oral pain drug beats morphine in animal study","url":"https://stock-news.laohu8.com/highlight/detail?id=2575728393","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575728393?lang=en_us&edition=fundamental","pubTime":"2025-10-16 22:58","pubTimestamp":1760626683,"startTime":"0","endTime":"0","summary":"BUZZ-MIRA Pharmaceuticals jumps as oral pain drug beats morphine in animal studyUpdates** Shares of drug developer MIRA Pharmaceuticals MIRA.O rise 52.3% to $2.01, nearly one-year high** Late on Wednesday, company said its experimental oral drug, Mira-55, eased pain and reduced swelling better than injected morphine in a pre-clinical animal study for chronic inflammatory pain** Mira-55 brought pain levels back to normal and directly reduced inflammation by targeting the CB2 receptor - MIRA** CB2 receptors are expressed in immune cells and are involved in the regulation of immune responses and inflammation** Company says morphine only partially reduced inflammation** Data supports marketing application plans for Mira-55 for chronic inflammatory pain - MIRA** Including session's move, shares up ~75% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL3N3VX163:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2575742169","title":"BUZZ-Becton falls on CFO exit, preliminary Q4 revenue miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2575742169","media":"Reuters","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575742169?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:58","pubTimestamp":1760623119,"startTime":"0","endTime":"0","summary":"BUZZ-Becton falls on CFO exit, preliminary Q4 revenue miss** Medical device maker Becton Dickinson's BDX.N shares fall 2.7% to $181.78 during market open** Co's CFO Chris DelOrefice to leave on December 5 to pursue new opportunity; search for permanent successor underway** Co names Vitor Roque, senior VP of finance, interim CFO ** BDX says vaccine-related devices and academic research demand were weaker than expected** Co reports preliminary Q4 revenue of $5.9 billion vs analysts' estimate of $5.91 billion - data compiled by LSEG ** RBC analysts say preliminary results came in slightly below the low end of the company's outlook** Brokerage J.P.Morgan says challenges in Pharma Systems and Biosciences have continued to be less transient than hoped for** Including session moves, stock down ~18% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL3N3VX0JS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1084165304.USD","BK4082","LU1244550494.USD","LU1496350171.SGD","LU0976567544.SGD","LU1670627923.USD","LU2430703178.SGD","LU0238689110.USD","LU1670628061.USD","LU2054465674.USD","LU2023250330.USD","LU0417517546.SGD","LU0820561818.USD","LU0648000940.SGD","LU0170899867.USD","LU0149725797.USD","LU0289739343.SGD","LU1571399168.USD","LU1854104046.USD","LU2552382215.SGD","LU0511384066.AUD","IE00BN8TJ469.HKD","LU1162221912.USD","LU0683600562.USD","LU1244550221.USD","LU1489326972.SGD","IE000M9KFDE8.USD","LU1201861165.SGD","BDX","IE00BZ1G4Q59.USD","LU0266013472.USD","LU0130103400.USD","LU0345770308.USD","LU1145028129.USD","IE00BJLML261.HKD","LU0320765646.SGD","IE00B1BXHZ80.USD","LU1496350502.SGD","MIRA","BK4550","LU1548497426.USD","LU2430703251.USD","LU0234572021.USD","LU2552382058.USD","LU2381873111.SGD","IE00BFXG1179.USD","LU1974910355.USD","LU0820562030.AUD","LU0882574139.USD","LU0820561909.HKD"],"gpt_icon":0},{"id":"2575741918","title":"BUZZ-U.S. STOCKS ON THE MOVE-United Airlines, Fossil Group, T-Mobile","url":"https://stock-news.laohu8.com/highlight/detail?id=2575741918","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575741918?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:11","pubTimestamp":1760620298,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-United Airlines, Fossil Group, T-MobileEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL6N3VX0LX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMC","SG9999001143.SGD","LU0130102774.USD","BK4598","FOSL","TMUS","MIRA","NEM","LU1316542783.SGD","NIO.SI","SATL","LU0106261372.USD","LU1066051225.USD","LU0642271901.SGD","PRAX","LU0496367417.USD","UAL","IE00B7SZLL34.SGD","GRAL","LU1814569148.SGD","IE00B29SXL02.USD","SCHW","LU1023059493.AUD","TRV","LU1506573853.SGD","HPE","AEP","TMO","AU","LU1046421795.USD","BK4161","BK4589","SNA","BK4570","JACK","KEY","LU0198837287.USD","JBHT","DFLI","LU0689472784.USD","EVS.SI","LU0128525929.USD","LU0976567544.SGD","BK4168","HYPR","LU0251131958.USD"],"gpt_icon":1},{"id":"2575743673","title":"Mira Pharmaceuticals announces preclinical data on oral Mira-55","url":"https://stock-news.laohu8.com/highlight/detail?id=2575743673","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575743673?lang=en_us&edition=fundamental","pubTime":"2025-10-16 19:40","pubTimestamp":1760614817,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals (MIRA) announced new preclinical data showing that oral Mira-55 normalized pain and significantly reduced inflammation, outper...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-announces-preclinical-data-on-oral-mira-55-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-announces-preclinical-data-on-oral-mira-55-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2575124087","title":"Mira Pharmaceuticals Shares up 75.7% Premarket After Co's Experimental Oral Pain Drug Outperforms Morphine in Animal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2575124087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575124087?lang=en_us&edition=fundamental","pubTime":"2025-10-16 18:31","pubTimestamp":1760610716,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nFWN3VW2WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mirapharmaceuticals.com","stockEarnings":[{"period":"1week","weight":0.0672},{"period":"1month","weight":-0.0451},{"period":"3month","weight":-0.1419},{"period":"6month","weight":-0.073},{"period":"1year","weight":0.2451},{"period":"ytd","weight":-0.1589}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.","exchange":"NASDAQ","name":"Mira Pharma","nameEN":"Mira Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mira Pharma,MIRA,Mira Pharma股票,Mira Pharma股票老虎,Mira Pharma股票老虎国际,Mira Pharma行情,Mira Pharma股票行情,Mira Pharma股价,Mira Pharma股市,Mira Pharma股票价格,Mira Pharma股票交易,Mira Pharma股票购买,Mira Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}